LB919 Vigxbsa in a pediatric population: a novel tool for evaluating atopic dermatitis severity and responsiveness

Abstract

Assessing severity of atopic dermatitis(AD) plays a key role in determining treatment choice and therapy escalation, but there are currently few severity assessments practical for clinical use. The EASI is a comprehensive severity assessment utilized in clinical trials but is considered too cumbersome for clinical use. The vIGA is a quick severity assessment for AD but fails to incorporate disease extent. A vIGAxBSA calculation has shown promise as a quick assessment which incorporates extent but has not been evaluated in a “real-world” non-clinical trial setting over time.